Teva
This article was originally published in The Tan Sheet
Executive Summary
Israel-based firm buys Copley for $220 mil. in cash or $11 per share. Hoechst had owned 52% of Copley. The acquisition will add 52 OTC and Rx products to Teva's U.S. business, including generic versions of miconazole vaginal cream, men's and women's 2% minoxidil topical solutions, bromatapp extended-release tablets, clemastine syrup and doxylamine succinate tablets. Both firms have highlighted the potential for Rx-to-OTC switches following the acquisition
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning